Compare Crispr Therapeutics AG (CRSP) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lufax Holding Ltd — how do they compare? Crispr Therapeutics AG trades at $50.63 (market cap $4.97B), while Lufax Holding Ltd trades at $1.31 (market cap $2.41B). The key difference: Crispr Therapeutics AG is far larger — about 2.1× Lufax Holding Ltd's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| CRSP | LU | |
|---|---|---|
Market Cap | $4.97B | $2.41B |
Sector | Health | Technology |
52-Week High | $76.78 | $4.40 |
52-Week Low | $44.34 | $1.23 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
LU trades at $1.25, down 6.72% over 24 hours, with technical indicators signaling a bearish trend. The stock shows weak profitability with a -9.08% net margin and negative ROE of -2.6%, though valuation ratios like P/S of 0.33 and P/B of 0.1 appear low. Recent news highlights multiple class-action lawsuits filed against the company, alleging securities fraud between April 2023 and January 2025.
Outlook remains challenged by legal risks and poor earnings, but low valuations may attract speculative interest. Key risks include ongoing litigation and sustained unprofitability, while analyst consensus leans bullish with 62% buy ratings, suggesting potential recovery if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
